Introduction
============

Acute respiratory distress syndrome (ARDS) is a potentially fatal disease with high mortality. Our aim was to summarize the current evidence for use of neuromuscular blocking agents (NMBA) in the early phase of ARDS.

Methods
=======

A systematic review and meta-analysis of publications between 1966 and 2012. The Medline and CENTRAL databases were searched for studies on NMBA in patients with ARDS. The meta-analysis was limited to: randomized controlled trials; adult human patients with ARDS or acute lung injury; and use of any NMBA in one arm of the study compared with another arm without NMBA. The outcomes assessed were: overall mortality, ventilator-free days, time of mechanical ventilation, adverse events, and changes in gas exchange, in ventilator settings, and in respiratory mechanics.

Results
=======

Three randomized controlled trials covering 431 participants were included. Patients treated with NMBA showed less mortality (risk ratio, 0.71 (95% CI, 0.55 to 0.90); number needed to treat, 1 to 7), more ventilator-free days at day 28 (*P*= 0.020), higher PaO~2~to FiO~2~ratios (*P*= 0.004), and less barotraumas (*P*= 0.030). The incidence of critical illness neuromyopathy was similar (*P*= 0.540).

Conclusion
==========

The use of NMBA in the early phase of ARDS improves outcome.
